Immunohistochemical differentiation between chronic enteropathy associated with SLCO2A1 gene and other inflammatory bowel diseases.
- Author:
Satoko YAMAGUCHI
1
;
Shunichi YANAI
;
Shotaro NAKAMURA
;
Keisuke KAWASAKI
;
Makoto EIZUKA
;
Noriyuki UESUGI
;
Tamotsu SUGAI
;
Junji UMENO
;
Motohiro ESAKI
;
Takayuki MATSUMOTO
Author Information
- Publication Type:Original Article
- Keywords: SLCO2A1; Chronic enteropathy; Crohn disease; Behcet syndrome; Immunohistochemistry
- MeSH: Behcet Syndrome; Crohn Disease; Endothelial Cells; Humans; Immunohistochemistry; Inflammatory Bowel Diseases*; Ulcer
- From:Intestinal Research 2018;16(3):393-399
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: We recently identified recessive mutations in the solute carrier organic anion transporter family member 2A1 gene (SLCO2A1) as causative variants of chronic enteropathy associated with SLCO2A1 (CEAS). The aim of this study was to evaluate SLCO2A1 protein expression in the intestinal tissues of patients with CEAS, intestinal Behçet's disease (BD), simple ulcer (SU), and Crohn's disease (CD). METHODS: Immunohistochemical staining using a polyclonal anti-SLCO2A1 antibody was performed on the resected intestinal specimens from 13 cases of CD, 9 cases of intestinal BD/SU, and 3 cases of CEAS. The extent of SLCO2A1 expression was determined by counting positively-staining vascular endothelial cells and scored as 0 (no cells), 1 (1%–30% cells), 2 (31%–60%), or 3 (>60%). The intensity of SLCO2A1 expression was scored either as 0 (negative), 1 (intermediate), or 2 (strong). The extent score and intensity score were summed for the final score of 0, 2, 3, 4, or 5. RESULTS: SLCO2A1 protein expression was observed in 1 of 3 cases of CEAS (33%), all 13 cases of CD (100%), and all 9 cases of BD/SU (100%). The mean final expression scores of CEAS, CD, and BD/SU were 1.6 (range, 0–5), 4.8 (range, 4–5), and 4.3 (range, 4–5), respectively. The final expression score in CEAS was significantly lower than in CD (P=0.03). CONCLUSIONS: Immunohistochemical staining of the SLCO2A1 protein is considered useful to distinguish CEAS from other inflammatory bowel diseases.
